5,563
Views
0
CrossRef citations to date
0
Altmetric
Editorial

TLR3 Agonists as Immunotherapeutic Agents

&
Pages 137-140 | Published online: 05 Mar 2010

Bibliography

  • Iwasaki A , MedzhitovR: Toll-like receptor control of the adaptive immune responses.Nat. Immunol.5(10) , 987–995 (2004).
  • Matsumoto M , FunamiK, TanabeMet al.: Subcellular localization of Toll-like receptor 3 in human dendritic cells.J. Immunol.171(6) , 3154–3162 (2003).
  • Tanaka J , WatanabeN, KidoMet al.: Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions.Clin. Exp. Allergy39(1) , 89–100 (2009).
  • Rozis G , BenlahrechA, DuraisinghamSet al.: Human Langerhans‘ cells and dermal-type dendritic cells generated from CD34 stem cells express different toll-like receptors and secrete different cytokines in response to toll-like receptor ligands.Immunology124(3) , 329–338 (2008).
  • Coley WB II: Contribution to the knowledge of sarcoma. Ann. Surg.14(3) , 199–220 (1891).
  • Field AK , TytellAA, LampsonGP, HillemanMR: Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes.Proc. Natl Acad. Sci. USA58(3) , 1004–1010 (1967).
  • Gitlin L , BarchetW, GilfillanSet al.: Essential role of MDA-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus.Proc. Natl Acad. Sci. USA103(22) , 8459–8464 (2006).
  • Trumpfheller C , CaskeyM, NchindaGet al.: The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.Proc. Natl Acad. Sci. USA105(7) , 2574–2579 (2008).
  • Carter WA , PithaPM, MarshallLWet al.: Structural requirements of the rI n -rC n complex for induction of human interferon.J. Mol. Biol.70(3) , 567–587 (1972).
  • Levy HB , BaerG, BaronSet al.: A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates.J. Infect. Dis.132(4) , 434–439 (1975).
  • Gowen BB , WongMH, JungKHet al.: TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules.J. Immunol.178(8) , 5200–5208 (2007).
  • Bagchi A , HerrupEA, WarrenHSet al.: MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists.J. Immunol.178(2) , 1164–1171 (2007).
  • Nicodemus CF , WangL, LucasJet al.: Toll like receptor-3 as a target to enhance bioactivity of cancer immunotherapy.Am. J. Obstet. Gynecol. DOI:10.1016/j.ajog.2009.12.001 (2010) (Epub ahead of print).
  • Gowen BB , HoopesJD, WongMHet al.: TLR3 deletion limits mortality and disease severity due to Phlebovirus infection.J. Immunol.177(9) , 6301–6307 (2006).
  • Ichinohe T , TamuraS, KawaguchiAet al.: Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.J. Infect. Dis.196(9) , 1313–1320 (2007).
  • Lombardi VC , RuscettiFW, DasGJet al.: Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome.Science326(5952) , 585–589 (2009).
  • Wang B , TripplerM, PeiRet al.: Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication.J. Hepatol.51(6) , 1037–1045 (2009).
  • Neves PC , MatosDC, MarcovistzR, GallerR: TLR expression and NK cell activation after human yellow fever vaccination.Vaccine27(41) , 5543–5549 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.